Literature DB >> 15770641

CNS recurrence following CD34+ peripheral blood stem cell transplantation in stage 4 neuroblastoma.

Hyoung Soo Choi1, Sang Hyeok Koh, Eun Sil Park, Hee Young Shin, Hyo Seop Ahn.   

Abstract

We report here central nervous system (CNS) recurrence in neuroblastoma (NBL) after CD34(+) peripheral blood stem cell transplantation (PBSCT). Fifteen stage 4 NBL patients underwent CD34(+) transplantation with myeloablative chemotherapy consisting of carboplatin, etoposide, and melphalan. There were three primary site recurrences and five distant metastases including four brain metastases (two isolated CNS recurrences) at 4-7 months after CD34(+) transplantation. Three of four patients died of CNS progressive disease at 2, 8, and 9 months after recurrence and the remaining single patient was lost to follow-up. CNS recurrence in NBL is fatal and requires identification of risk factors and more effective treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15770641     DOI: 10.1002/pbc.20315

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  3 in total

1.  Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma.

Authors:  Kim Kramer; Brian H Kushner; Shakeel Modak; Neeta Pandit-Taskar; Peter Smith-Jones; Pat Zanzonico; John L Humm; Hong Xu; Suzanne L Wolden; Mark M Souweidane; Steven M Larson; Nai-Kong V Cheung
Journal:  J Neurooncol       Date:  2009-11-05       Impact factor: 4.130

2.  Brain metastasis in children with stage 4 neuroblastoma after multidisciplinary treatment.

Authors:  Jia Zhu; Juan Wang; Zi-Jun Zhen; Su-Ying Lu; Fei Zhang; Fei-Fei Sun; Peng-Fei Li; Jun-Ting Huang; Rui-Qing Cai; Xiao-Fei Sun
Journal:  Chin J Cancer       Date:  2015-09-14

3.  Significance of hematopoietic surface antigen CD34 in neuroblastoma prognosis and the genetic landscape of CD34-expressing neuroblastoma CSCs.

Authors:  Natarajan Aravindan; Dinesh Babu Somasundaram; Terence S Herman; Sheeja Aravindan
Journal:  Cell Biol Toxicol       Date:  2020-09-26       Impact factor: 6.819

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.